TLTFF (Theralase Technologies) Inventories, Finished Goods: $0.14 Mil (As of Mar. 2026)


TLTFF Theralase Technologies Inc TLTFF
46 GF Score
Price $0.18
GF Value $0.13
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Theralase Technologies Inventories, Finished Goods?

Theralase Technologies TLTFF -0.98% 46 Inventories, Finished Goods is $0.14 Mil as of Mar. 2026. GuruFocus rates TLTFF with a GF Score™ of 46/100 and a GF Value™ of $0.13 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Theralase Technologies's quarterly finished goods increased from Sep. 2025 ($0.10 Mil) to Dec. 2025 ($0.15 Mil) but then declined from Dec. 2025 ($0.15 Mil) to Mar. 2026 ($0.14 Mil).

Theralase Technologies's annual finished goods declined from Dec. 2023 ($0.12 Mil) to Dec. 2024 ($0.08 Mil) but then increased from Dec. 2024 ($0.08 Mil) to Dec. 2025 ($0.15 Mil).

Theralase Technologies Inventories, Finished Goods Historical Data

* Premium members only.

The historical data trend for Theralase Technologies's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theralase Technologies Inventories, Finished Goods Chart

Theralase Technologies Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Inventories, Finished Goods
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.26 0.21 0.12 0.08 0.15

Theralase Technologies Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Inventories, Finished Goods Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.07 0.14 0.10 0.15 0.14
TLTFF
46GF Score
Theralase Technologies Inc TLTFF
Inventories, Finished Goods is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Theralase Technologies Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.

What does a Inventories, Finished Goods of $0.14 Mil mean?
Theralase Technologies (TLTFF) has a Inventories, Finished Goods of $0.14 Mil as of Mar. 2026. Finished goods are inventory items that are complete and ready to be sold. View historical data on Theralase Technologies and its competitors.
Is Theralase Technologies' Inventories, Finished Goods too high?
Theralase Technologies' current Inventories, Finished Goods is $0.14 Mil. Overall, Theralase Technologies has a GF Score™ of 46/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Theralase Technologies' Inventories, Finished Goods compare to ABT and SYK?
Theralase Technologies' Inventories, Finished Goods of $0.14 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Finished Goods for a Medical Devices & Instruments company?
A good Inventories, Finished Goods depends on the Medical Devices & Instruments industry context. However, Inventories, Finished Goods should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Finished Goods mean?
A high Inventories, Finished Goods can signal that a stock is expensive relative to its fundamentals. Finished goods are inventory items that are complete and ready to be sold. View historical data on Theralase Technologies and its competitors. Theralase Technologies's current Inventories, Finished Goods is $0.14 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Theralase Technologies stock overvalued right now?
Based on GuruFocus' analysis, Theralase Technologies (TLTFF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.13, compared to a current price of $0.18 — trading 41.6% above its estimated fair value. The current Inventories, Finished Goods is $0.14 Mil. Theralase Technologies' overall GF Score™ is 46/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Finished Goods calculated?
Inventories, Finished Goods is calculated from a company's financial statements. For Theralase Technologies (TLTFF), the current Inventories, Finished Goods is $0.14 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Theralase Technologies (TLTFF) Overvalued in 2026?

Based on GuruFocus' analysis, Theralase Technologies stock appears to be overvalued. The current stock price of $0.18 is trading 41.6% above its estimated GF Value™ of $0.13. GuruFocus considers Theralase Technologies to be Significantly Overvalued.

Key valuation signals for TLTFF:

  • Inventories, Finished Goods: $0.14 Mil
  • GF Value™: $0.13 vs. price of $0.18 (41.6% above fair value)
  • GF Score™: 46/100 with 4 warning signs

No single metric tells the full story. See the TLTFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Theralase Technologies Business Description

Other Exchanges TTX:GermanyTLT:Canada
Address 41 Hollinger Road, Toronto, ON, CAN, M4B 3G4
Theralase Technologies Inc brings CLT to patients and personalized ACT to patients based on individual tissue characteristics. It is two separate reportable operating divisions; the Drug Division and the Device Division. The Drug Division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs), and activates them with proprietary and patent-pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The Device Division designs develops, manufactures, and markets proprietary super-pulsed laser technology indicated and cleared by Health Canada and the Food and Drug Administration (FDA) for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions.
46GF Score

Get the complete analysis for TLTFF

Inventories, Finished Goods is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.18
Price
$0.13
GF Value